Sign in Register

Drug class

Drugs To Treat Hereditary Tyrosinemia

"Drugs to treat hereditary tyrosinemia" is an indication-based therapeutic grouping rather than a distinct biochemical class, primarily represented by 4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitors such as nitisinone. Read more about Drugs To Treat Hereditary Tyrosinemia

9 drugs in this class 7 manufacturers

Related classes & indications

Antihyperglycemic-dipeptidyl peptidase-4 (DPP-4) InhibitorsEndocrine & metabolic · 49 prescription drugs 5 Alpha-Reductase InhibitorsEndocrine & metabolic · 44 prescription drugs Hereditary Tyrosinemia Type ITop indication · 9 prescription drugs

Showing 1–9 of 9 drugs

Sort

ORFADIN (nitisinone)

DRUGS TO TREAT HEREDITARY TYROSINEMIA · HEREDITARY TYROSINEMIA TYPE I ·+1

BIOVITRUM

ORFADIN (nitisinone)

DRUGS TO TREAT HEREDITARY TYROSINEMIA · HEREDITARY TYROSINEMIA TYPE I ·+1

BIOVITRUM

NITYR (nitisinone)

DRUGS TO TREAT HEREDITARY TYROSINEMIA · HEREDITARY TYROSINEMIA TYPE I ·+1

CYCLE PHARMACEU

NITISINONE

DRUGS TO TREAT HEREDITARY TYROSINEMIA · HEREDITARY TYROSINEMIA TYPE I ·+1

PAR HEALTH USA,

NITISINONE

DRUGS TO TREAT HEREDITARY TYROSINEMIA · HEREDITARY TYROSINEMIA TYPE I ·+1

TORRENT PHARMAC

NITISINONE

DRUGS TO TREAT HEREDITARY TYROSINEMIA · HEREDITARY TYROSINEMIA TYPE I ·+1

BRYANT RANCH PR

NITISINONE

DRUGS TO TREAT HEREDITARY TYROSINEMIA · HEREDITARY TYROSINEMIA TYPE I ·+1

ANALOG PHARMA,

NITISINONE

DRUGS TO TREAT HEREDITARY TYROSINEMIA · HEREDITARY TYROSINEMIA TYPE I ·+1

ETON PHARMACEUT

HARLIKU (nitisinone)

DRUGS TO TREAT HEREDITARY TYROSINEMIA · HEREDITARY TYROSINEMIA TYPE I ·+1

CYCLE PHARMACEU

Filter & compare in the drug finder → Opens the drug finder with Drugs To Treat Hereditary Tyrosinemia preselected. Add indication or manufacturer filters there.

About Drugs To Treat Hereditary Tyrosinemia.

"Drugs to treat hereditary tyrosinemia" is an indication-based therapeutic grouping rather than a distinct biochemical class, primarily represented by 4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitors such as nitisinone.

These agents work by reversibly inhibiting the catabolic enzyme upstream of fumarylacetoacetate hydrolase, thereby preventing the synthesis and accumulation of toxic metabolites such as succinylacetone, fumarylacetoacetate, and maleylacetoacetate.

Used in conjunction with dietary restriction of phenylalanine and tyrosine, this therapy is indicated for hereditary tyrosinemia type 1 to prevent severe liver failure, renal dysfunction, porphyric crises, and the development of hepatocellular carcinoma.

medlineplus.gov
"Drugs to treat hereditary tyrosinemia" is an indication-based therapeutic grouping rather than a distinct biochemical class, primarily represented by 4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitors such as nitisinone
fda.gov
"Drugs to treat hereditary tyrosinemia" is an indication-based therapeutic grouping rather than a distinct biochemical class, primarily represented by 4-hydroxyphenylpyruvate dioxygenase (HPPD) inhibitors such as nitisinone
nih.gov
These agents work by reversibly inhibiting the catabolic enzyme upstream of fumarylacetoacetate hydrolase, thereby preventing the synthesis and accumulation of toxic metabolites such as succinylacetone, fumarylacetoacetate, and maleylacetoacetate
nih.gov
These agents work by reversibly inhibiting the catabolic enzyme upstream of fumarylacetoacetate hydrolase, thereby preventing the synthesis and accumulation of toxic metabolites such as succinylacetone, fumarylacetoacetate, and maleylacetoacetate Used in conjunction with dietary restriction of phenylalanine and tyrosine, this therapy is indicated for hereditary tyrosinemia type 1 to prevent severe liver failure, renal dysfunction, porphyric crises, and the development of hepatocellular carcinoma
uspharmacist.com
Used in conjunction with dietary restriction of phenylalanine and tyrosine, this therapy is indicated for hereditary tyrosinemia type 1 to prevent severe liver failure, renal dysfunction, porphyric crises, and the development of hepatocellular carcinoma
fda.gov
Used in conjunction with dietary restriction of phenylalanine and tyrosine, this therapy is indicated for hereditary tyrosinemia type 1 to prevent severe liver failure, renal dysfunction, porphyric crises, and the development of hepatocellular carcinoma